The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2)

Autor: Amparo Larrauri, Pedro Pechirra, Manuel García Cenoz, Lisa Domegan, Ausenda Machado, Daniela Pitigoi, Raquel Guiomar, Francisco Pozo, Gheorghe Necula, Daniel Castrillejo, Silvia Jiménez-Jorge
Rok vydání: 2015
Předmět:
vacunas de la gripe
Male
potencia vacunal
Time Factors
Gripe
humanos
Efetividade da Vacina Antigripal
adolescente
virus de la influenza A
Influenza A Virus
H1N1 Subtype
Odds Ratio
vigilancia centinela
Influenza vaccine effectiveness
Child
mediana edad
media_common
Vaccine effectiveness
anciano
Influenza vaccine
Confounding
Vaccination
virus diseases
Vacina da Gripe
adulto
Middle Aged
Random effects model
cociente de probabilidades relativas
3. Good health
Europe
Infectious Diseases
Influenza A virus
Influenza Vaccines
Child
Preschool
Molecular Medicine
Female
Seasons
Test-negative design
Adult
medicine.medical_specialty
Adolescent
estudios de casos y controles
Multicentre study
vacunación
factores de tiempo
Unión Europea
Internal medicine
Immunology and Microbiology(all)
Influenza
Human
medicine
media_common.cataloged_instance
Humans
I-MOVE
European Union
European union
Vaccine Potency
Aged
lactante
General Veterinary
General Immunology and Microbiology
business.industry
Influenza A Virus
H3N2 Subtype
Cuidados de Saúde
Public Health
Environmental and Occupational Health
Infant
Newborn
Infant
Odds ratio
veterinary(all)
Influenza
estaciones (meteorología)
respiratory tract diseases
Study heterogeneity
Sample size determination
Case-Control Studies
Immunology
business
Sentinel Surveillance
Zdroj: Repisalud
Instituto de Salud Carlos III (ISCIII)
Popis: BACKGROUND: In the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013-2014, we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in six European Union (EU) countries to measure 2013-2014 influenza VE against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Influenza A(H3N2) and A(H1N1)pdm09 viruses co-circulated during the season. METHODS: Practitioners systematically selected ILI patients to swab within eight days of symptom onset. We compared cases (ILI positive to influenza A(H3N2) or A(H1N1)pdm09) to influenza negative patients. We calculated VE for the two influenza A subtypes and adjusted for potential confounders. We calculated heterogeneity between sites using the I(2) index and Cochrane's Q test. If the I(2) was 49% we used a two-stage random effects model. RESULTS: We included in the A(H1N1)pdm09 analysis 531 cases and 1712 controls and in the A(H3N2) analysis 623 cases and 1920 controls. For A(H1N1)pdm09, the Q test (p=0.695) and the I(2) index (0%) suggested no heterogeneity of adjusted VE between study sites. Using a one-stage model, the overall pooled adjusted VE against influenza A(H1N1)pdm2009 was 47.5% (95% CI: 16.4-67.0). For A(H3N2), the I(2) was 51.5% (p=0.067). Using a two-stage model for the pooled analysis, the adjusted VE against A(H3N2) was 29.7 (95% CI: -34.4-63.2). CONCLUSIONS: The results suggest a moderate 2013-2014 influenza VE against A(H1N1)pdm09 and a low VE against A(H3N2). The A(H3N2) estimates were heterogeneous among study sites. Larger sample sizes by study site are needed to prevent statistical heterogeneity, decrease variability and allow for two-stage pooled VE for all subgroup analyses. European Center for Disease Prevention and Control
Databáze: OpenAIRE
Externí odkaz: